- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05988918
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors
This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients.
Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive calendar days, then take a drug holiday for 2 consecutive days before repeating the 5 days on-2 days off cycle in sets of 4 weeks or 28 calendar days. Subjects will be asked to keep a pill diary noting the date they take their study drug.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Cancer AnswerLine
- Phone Number: 1-800-865-1125
- Email: CancerAnswerLine@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- Rogel Cancer Center
-
Principal Investigator:
- Vaibhav Sahai, MBBS, MS
-
Contact:
- Vaibhav Sahai, MBBS, MS
- Phone Number: 734-936-4991
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Eligibility Criteria:
Patients with histological or cytological confirmation of advanced cancer per specific cohort.
- Cohort 1: Pancreatic adenocarcinoma or adenosquamous carcinoma who have progressed or deemed intolerant of the standard of care chemotherapy regimens.
- Cohort 2: Pancreatic or gastrointestinal neuroendocrine tumor or carcinoma with Ki-67 > 20% who have progressed or deemed intolerant of at least first-line standard of care systemic therapy.
Cohort 3: The subject has histologically proven prostate cancer who have progressed or deemed intolerant of at least first-line standard of care systemic therapy with radiologic evidence of metastases and at least one of the following:
- Small cell or neuroendocrine morphology on the basis of tissue sample.
- Prostate adenocarcinoma with IHC staining for neuroendocrine markers (e.g., chromogranin and synaptophysin).
- Presence of visceral metastases or high-volume disease (> 4 sites of metastases) with a PSA ≤ 5.
- Serum chromogranin A level ≥ 5x upper limit of normal (ULN) and/or serum neuron specific enolase (NSE) ≥ 2x ULN.
- Trans-differentiated carcinoma or poorly-differentiated carcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
- Must be ≥ 18 years of age.
- Evaluable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
- Ability to understand and willingness to sign IRB-approved informed consent.
- Willing to provide archived tissue, if available, from a previous diagnostic biopsy.
- Must be able to tolerate CT and/or MRI with contrast.
- At least 4 weeks from major surgery with resolution of any sequela to date of enrollment
Laboratory values ≤2 weeks during screening must be:
- Platelet count ≥ 75,000 cells/mm3
- Absolute neutrophil count ≥ 1500 cells/mm3
- Hemoglobin ≥ 9 g/dL
- AST/ALT ≤ 3x upper limit of normal [ULN], or (≤ 5x ULN if liver metastasis present)
- Bilirubin ≤ 1.5x ULN, or (≤ 2.5 x ULN for subjects with Gilbert's syndrome)
- Albumin ≥ 3 g/dL
- Serum creatinine clearance CrCl ≥ 50 mL/min per Cockcroft-Gault Formula
- INR ≤ 1.5 (or <2.0 if on anticoagulants)
- Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must agree to use acceptable highly effective contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive(s), intrauterine hormone releasing system (IUS), bilateral tubal occlusion or vasectomized partner) during and for 9 months after last study dose and must have a negative serum or urine pregnancy test during screening.
- Males with female partners (of childbearing potential) and female partners (of childbearing potential) with male partners must agree to use double barrier contraceptive measure (a combination of male condom with either cap, diaphragm or sponge with spermicide) in addition to oral contraception, or avoidance of intercourse during the study and for 6 months after last study dose is received.
- Female patients must not be pregnant, have a positive pregnancy test, breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 9 months after the last dose of study treatment.
- Male patients must be willing to abstain from donating sperm during treatment and for 6 months after completion of study treatment.
- No evidence of active infection and no serious infection within the past 30 days. Patient must have completed antibiotic course.
- No known cerebral metastasis, central nervous system (CNS), or epidural tumor (unless previously treated, asymptomatic and stable for at least 3 months).
- No active heart disease including but not limited to myocardial infarction that is <3 months prior to registration, symptomatic congestive heart failure (NYHA class 3 or 4), symptomatic coronary artery disease, symptomatic angina pectoris.
- No history of acute cerebrovascular disease, arterial embolism, pulmonary embolism, percutaneous angioplasty, or coronary artery bypass surgery within 6 months prior to registration.
- No pre-existing coagulopathy, or serious bleeding within 3 months prior to registration.
- No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cancer, localized prostate cancer (Gleason score <8), or adequately treated cancer from which the patient has been disease-free for at least 3 years prior to registration.
- Must not have uncontrolled diarrhea at the time of enrollment.
- Patients must not use a chronic daily medication known to be a strong or moderate inhibitor of CYP1A2, CYP2C8 or CYP3A4 at registration (as per Appendix II).
- Patients must have recovered to baseline or ≤ grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless adverse event(s) is deemed clinically non-significant and/or stable on supportive therapy.
- Patients must not have uncontrolled hypertension defined as blood pressure >150/90 despite optimal medical management.
- No known hypersensitivity to gelatin or lactose monohydrate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Pancreatic adenocarcinoma
|
160 mg, PO, Once daily 5 days on and 2 days off
Other Names:
|
Experimental: Cohort 2
Pancreatic or gastrointestinal neuroendocrine neoplasms with Ki-67 > 20%
|
160 mg, PO, Once daily 5 days on and 2 days off
Other Names:
|
Experimental: Cohort 3
Neuroendocrine prostate carcinoma with Ki-67 > 20%
|
160 mg, PO, Once daily 5 days on and 2 days off
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 4 months after initiating study drug
|
Determining efficacy using proportion of patients alive and progression-free at 4 months within each cancer subtype
|
4 months after initiating study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) within each cancer subtype
Time Frame: up to 18 months from treatment discontinuation
|
The ORR will be assessed per RECIST v1.1 criteria (Cohort 1 and 2) or combined RECIST v1.1 + PCWG3 criteria (Cohort 3).
Partial or complete response will require confirmation on repeat scan at least 4 weeks from initial radiologic response
|
up to 18 months from treatment discontinuation
|
Duration of Response (DoR) within each cancer subtype
Time Frame: up to 18 months from treatment discontinuation
|
DoR will be measured from the start date of the best response achieved until the date of relapse (i.e., progression).
Continuing responders will be right-censored as of the most recent date on which their response status had been assessed.
DoR applies to only the patients who achieve either a complete response or a partial response.
|
up to 18 months from treatment discontinuation
|
Overall Survival (OS) within each cancer subtype
Time Frame: up to 18 months from treatment discontinuation
|
The OS will be defined from the date of treatment to either date of death or censoring and estimated using the product-limit method of Kaplan and Meier.
Follow-up time will be censored at the date of last disease evaluation.
|
up to 18 months from treatment discontinuation
|
Safety and tolerability in each cancer subtype
Time Frame: up to 30 days from treatment discontinuation
|
Adverse events (AEs) will be defined per the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.
|
up to 30 days from treatment discontinuation
|
Median Progression- Free Survival (PFS) within each cancer subtype
Time Frame: up to 18 months from treatment discontinuation
|
The PFS will be defined as time from date of initial treatment to date of radiological or clinical progression (leading to withdrawal from the study treatment), or death from any cause on study treatment, whichever comes first.
Follow-up time will be censored at the date of last disease evaluation.
|
up to 18 months from treatment discontinuation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vaibhav Sahai, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms, Complex and Mixed
- Pancreatic Diseases
- Pancreatic Neoplasms
- Neoplasms
- Carcinoma
- Carcinoma, Neuroendocrine
- Carcinoma, Adenosquamous
- Neuroendocrine Tumors
- Carcinoma, Islet Cell
Other Study ID Numbers
- UMCC 2023.005
- HUM00233810 (Other Identifier: University of Michigan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on ESK981
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of TestosteroneUnited States
-
University of Michigan Rogel Cancer CenterTerminatedRenal Cell Carcinoma, MetastaticUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States